Publications by authors named "David Heppner"

Claim this Profile
S
Structural Biology Enabling Drug Discovery.
David E Heppner, Simone V Bigi-Botterill, Andrew P Riley, Kelly Chibale, Craig W Lindsley

J Med Chem· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introduction to the themed collection on kinases.
Meizhong Jin, Hayley Binch, David E Heppner, Philip Jones

RSC Med Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies.
Tahereh Damghani, Surbhi P Chitnis, Omobolanle A Abidakun, Kishan B Patel, Kaly S Lin, David E Heppner

J Med Chem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Selectivity and Potency of SAr Covalent Inhibitors of NADPH Oxidase Enzymes.
Blessing C Ogboo, Kishan B Patel, Marta Massari, Sara Marchese, Joana Reis, David E Heppner

J Med Chem· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Activity Relationships of Inactive-Conformation Binding EGFR Inhibitors: Linking the ATP and Allosteric Pockets.
Surbhi P Chitnis, Florian Wittlinger, Mareike Möllers, Tyler J Hartman, Marcel Günther, David E Heppner

Arch Pharm (Weinheim)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lazertinib: breaking the mold of third-generation EGFR inhibitors.
Kishan B Patel, David E Heppner

RSC Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ascertaining a Structural Basis in Drug Discovery and Development.
David E Heppner

J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Discovery and Development Faces an Ominous Future from NIH Indirect Costs Rate Cuts.
David E Heppner

J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase Inhibitors.
Florian Wittlinger, Surbhi P Chitnis, Calvin D Pham, Tahereh Damghani, Kishan B Patel, David E Heppner

J Med Chem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demystifying Functional Parameters for Irreversible Enzyme Inhibitors.
David E Heppner, Blessing C Ogboo, Daniel A Urul, Earl W May, Erik M Schaefer

J Med Chem· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural Analysis of the Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase.
Tyler S Beyett, Jaimin K Rana, Ilse K Schaeffner, David E Heppner, Michael J Eck

ChemMedChem· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma.
Nur P Damayanti, Ricardo A Cordova, Christopher Rupert, Ilaria Delle Fontane, Li Shen, David E Heppner

Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Twelve CO molecules for the price of one. A simple water-soluble organometallic CORM, [Mn(CO)(μ-OH)].
David C Lacy, David E Heppner, Brian Buckley, Justin Griffiths, Parami S Gunasekera

Polyhedron· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors.
Florian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D Pham, David E Heppner

Commun Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pitfalls and Considerations in Determining the Potency and Mutant Selectivity of Covalent Epidermal Growth Factor Receptor Inhibitors.
Kristopher W Hoyt, Daniel A Urul, Blessing C Ogboo, Florian Wittlinger, Stefan A Laufer, David E Heppner

J Med Chem· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Constitutive EGFR Kinase Dimer to Study Inhibitor Pharmacology.
Justin J Kim, Ilse K Schaeffner, David E Heppner, Ciric To, Pasi A Jänne

Mol Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor.
Debanjan Bhattacharjee, Jaweria Bakar, Surbhi P Chitnis, Erin L Sausville, Kumar Dilip Ashtekar, David E Heppner

Cell Chem Biol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors.
David Heppner, Florian Wittlinger, Blessing Ogboo, Ekaterina Shevchenko, Tahereh Damghani

Res Sq· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.
Tahereh Damghani, Florian Wittlinger, Tyler S Beyett, Michael J Eck, Stefan A Laufer, David E Heppner

Methods Enzymol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448).
David E Heppner, Florian Wittlinger, Tyler S Beyett, Tatiana Shaurova, Daniel A Urul

ACS Med Chem Lett· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors.
Yoshihisa Kobayashi, Geoffrey R Oxnard, Elizabeth F Cohen, Navin R Mahadevan, Joao V Alessi, David E Heppner

Nat Commun· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC.
Thomas W Gero, David E Heppner, Tyler S Beyett, Ciric To, Seth C Azevedo

Bioorg Med Chem Lett· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Architecture of the NADPH oxidase family of enzymes.
Blessing C Ogboo, Uriy V Grabovyy, Aniket Maini, Scott Scouten, Albert van der Vliet, David E Heppner

Redox Biol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors.
Tyler S Beyett, Ciric To, David E Heppner, Jaimin K Rana, Anna M Schmoker

Nat Commun· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.
Ciric To, Tyler S Beyett, Jaebong Jang, William W Feng, Magda Bahcall, David E Heppner

Nat Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis